Efavirenz/Efavirenz API

Name	Efavirenz/Efavirenz
Chinese name	依非韦仑/依法韦仑
Cas Number	154598-52-4
Source	India
Qualifications	USDMF/-/-/-/-

Efavirenz was approved by the U.S. Food and Drug Administration in September 1998 and became the 14th approved antiretroviral drug in the world. In the same year, the U.S. Department of Health and Human Services (DHHS) updated its medication guidelines, Efavirenz is included in the first-line treatment and is recommended for HIV-naïve patients. Efavirenz is an antiretroviral drug in the category of non-nucleoside reverse transcriptase inhibitors. Both nucleoside-based RTI (reverse transcriptase inhibitor) and non-nucleoside-based RTI are intended to inhibit the same target, which is reverse transcriptase. It is generally believed that protease inhibitor drugs are more likely to cause dyslipidemia, while efavirenz has less effect on lipid metabolism. Relevant studies have shown that the clinical efficacy of efavirenz in the treatment of AIDS is better than nevirapine; the incidence of gastrointestinal symptoms, liver function abnormalities, and rashes in patients who use efavirenz is lower than that of nevirapine. Studies have also shown that the failure rate of the initial regimen based on nevirapine in the treatment of AIDS is higher than that of efavirenz. The size of the global anti-HIV drug market increased from 22.9 billion in 2013 to 33.96 billion in 2018, with a compound annual growth rate of 8.2%. It is estimated that by 2023, China's anti-HIV drug market will reach 4.96 billion yuan.

Hot Tags: efavirenz/efavirenz api, China, suppliers, manufacturers, factory, customized, price, pricelist, in stock, Perindopril Arginine API, Pregabalin API, Fulvestrant API, Rasagiline Mesylate API, Letrozole API, Cinacalcet Hydrochloride API

• Previous: Roxatidine Acetate API
• Next: Ulinastatin API